Safety analysis of gepants for migraine treatment: A pharmacovigilance study using the FDA Adverse Event Reporting System ( FAERS ) database

Key Points

• Gepants exhibit unique adverse event profiles, particularly gastrointestinal and neurological effects.
• Zavegepant, an intranasal agent, has been linked to respiratory irritation noted in the analysis.
• Utilizing the FDA Adverse Event Reporting System allows evaluation of post-marketing safety in migraine treatments.
• Continued monitoring supports safer, more personalized treatment strategies within migraine management.

Abstract